Q1 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
KisqaliⓇ gaining momentum globally, with increasing recognition
of its differentiated profile
GROWTH
Sales evolution
USD m, % cc
Ex-US
US
+81%
415
233
239
160
79
US metastatic BC
NBRx share1
R3M, %
13%
182
Q1 2022
Q1 2023
Feb 2022
KISQALI
28%
Q1 sales USD 415 million, +81% cc
US NBRX1 share doubled vs. PY to 28%
EU5 1L MBC NBRx share up to 38% (Q4'22)
vs. 32% (in Q3'22)
Feb 2023
Favorable NCCN2 guidelines positioning
Kisqali as only Category 1 treatment for 1L
mBC with Al
Positive readout of Ph3 NATALEE study
in eBC; data to be presented at upcoming
congress
mBC metastatic breast cancer. NBRX new to brand prescription. R3M rolling 3 months.
Q1 R3M. 2. NCCN Guidelines updated as of 27-Jan-2023.
eBC - early breast cancer. NCCN national comprehensive cancer network. Al-aromatase inhibitor. 1. Of CDK4/6 mBC market, US
16 Investor Relations | Q1 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation